| Marti Shedron, MS, CCC/SLP | |
|
849 Jeffco Blvd, Arnold, MO 63010-1409 | |
| (636) 282-5184 | |
| Not Available |
| Full Name | Marti Shedron |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 849 Jeffco Blvd, Arnold, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013496868 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Marti Shedron, MS, CCC/SLP 2121 Oakglen St, Imperial, MO 63052-4372 Ph: (314) 406-1158 | Marti Shedron, MS, CCC/SLP 849 Jeffco Blvd, Arnold, MO 63010-1409 Ph: (636) 282-5184 |
News Archive
OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.
Data show that Boehringer Ingelheim's second-generation protease inhibitor faldaprevir, when used in combination with pegylated interferon and ribavirin, was effective even with the presence of naturally-occurring mutant variants of the hepatitis C virus, such as the NS3 Q80K polymorphism
Salk Institute scientists have discovered the holy grail of endless youthfulness-at least when it comes to one type of human kidney precursor cell.
Covagen and Tanabe Research Laboratories U.S.A, Inc., a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation, today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012.
Lung cancer often metastasizes to the brain. Historically, brain metastases have been treated with whole-brain radiation therapy.
› Verified 7 days ago
Jane Elaine Davenport, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3488 Jeffco Blvd, Suite 102, Arnold, MO 63010 Phone: 636-464-5439 Fax: 636-464-5438 | |
Lydia Coffman, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1401 Ridgewood School Rd, Arnold, MO 63010 Phone: 636-282-1459 | |
Ariana Jane Jolley, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3488 Jeffco Blvd Ste 102, Arnold, MO 63010 Phone: 636-464-5439 | |
Carissa Lynn Dodge, MS CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 745 Jeffco Blvd, Arnold, MO 63010 Phone: 636-296-8000 | |
Rebecca D Cash, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3488 Jeffco Blvd, Ste 102, Arnold, MO 63010 Phone: 636-464-5439 Fax: 636-464-5438 | |
Mrs. Danielle Bamvakais, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 745 Jeffco Blvd, Arnold, MO 63010 Phone: 636-296-8000 |